logo
Share SHARE
FONT-SIZE Plus   Neg

Wolverine Worldwide And Forus SA Form JV In Colombia - Quick Facts

Wolverine Worldwide (WWW) and Forus SA announced the formation of a new joint venture, Lifestyle Brands of Colombia, to market footwear in Colombia.

Wolverine Worldwide noted that the joint venture will be granted the long-term distribution rights to market some of Wolverine's most significant brands, Merrell and Caterpillar Footwear, in the important Colombian market. Further, the venture will market Forus' well-established outdoor brand, RKF. Wolverine will own 51% of the new joint venture.

Wolverine said that as a second part of the business collaboration, it is purchasing a 49% stake in Forus' existing Colombian business, Forus SA Colombia, which currently has the rights to Wolverine's Hush Puppies and Cushe brands in Colombia. Forus SA Colombia currently owns and operates 23 retail locations and sells directly to Colombia's most important department stores and specialty footwear retailers.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
The Coca-Cola Company (KO) reported a profit for the first-quarter of 2017 that declined 20 percent from the prior year. Net revenues declined 11%, reflecting unfavorable impacts from structural changes of 10% and foreign currency of 1%. The company remains on track to deliver its underlying revenue and profit targets for the full year. Eli Lilly and Co. (LLY) reported a loss for the first quarter of 2017 compared to profit in the prior year, primarily hurt by lower operating income, partially offset by higher other income. But, quarterly revenue increased 7 percent, driven by 9 percent pharmaceutical volume growth from Trulicity, Taltz and other new products. Capricor Therapeutics, Inc., a clinical-stage biotechnology company for cardiac and other medical conditions, announced Tuesday positive six-month results from the randomized phase I/II HOPE clinical trial in Duchenne muscular dystrophy or DMD. The HOPE clinical trial was designed to evaluate the safety and exploratory efficacy of CAP-1002.
comments powered by Disqus
Follow RTT